KNC Laboratories Co.,Ltd.

As of March 31, 2026, KNC Laboratories Co.,Ltd. carries a market capitalization of 9.51B, placing it among publicly traded companies globally. Its enterprise value stands at 10.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

KNC Laboratories Co.,Ltd.'s next confirmed earnings release is scheduled for November 13, 2026.

As of March 31, 2026, KNC Laboratories Co.,Ltd. has 7.74M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, KNC Laboratories Co.,Ltd. maintains a current ratio of 2.87, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, KNC Laboratories Co.,Ltd.'s stock has gained approximately 9.53% over the past 52 weeks. The 50-day moving average sits at 1,247.70, while the 200-day moving average is 1,250.33.

As of March 31, 2026, KNC Laboratories Co.,Ltd. holds 2.17B in cash and equivalents against 3.60B in total debt, resulting in a net debt position of 1.42B. Total book value stands at 14.08B, with working capital of 5.08B providing operational flexibility.